Clinical Trial

Effect of the Consumption of Milk With Beta-casein A2A2, Milk With Beta-casein A1A2 and a Plant-based Drink on Metabolic Health in Adults: IMPA-CT Study

Study acronym: IMPA-CT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated April 23, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study was to identify and compare the effects of daily consumption of A2 milk, conventional milk, and an oat drink on bone health, cardiometabolic health, and immune system function in adults. Although cow's milk plays an important role in human nutrition, its proteins-particularly β-caseins-exhibit significant genetic diversity. Conventional milk typically contains a mix of A1 and A2 β-casein variants, whereas A2 milk contains exclusively the A2/A2 variant. The key difference between the two lies in a single amino acid at position 67: variant A1 contains histidine, which allows digestive enzymes to release the opioid peptide β-casomorphin-7 (BCM-7), while variant A2 contains proline, which prevents the release of this peptide. Consequently, the study is trying to answer the question of whether 12 weeks of consuming 500 ml of A2 milk daily-thereby eliminating dietary exposure to BCM-7-results in different outcomes for bone health (the primary measure), as well as for cardiometabolic health and immune function, when compared to consuming conventional milk or a plant-based oat drink in healthy adults aged 30-60.
Trial Details
NCT Number NCT07436260
Lead Sponsor Dawid Madej
Conditions Healthy Participants
Enrollment 150 participants
Start Date 2025-09-05
Primary Completion 2026-04-23 (estimated)
Study Completion 2026-04-23 (estimated)
Updated on ClinicalTrials.gov 2026-02-27